Express News | Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target

BenzingaJun 28 08:31 ET

TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35

TD Cowen analyst Tyler Van Buren maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41

Moomoo NewsJun 27 07:31 ET · Ratings

H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30

H.C. Wainwright analyst Yi Chen maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 24.

Moomoo NewsJun 27 06:31 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target

BenzingaJun 27 06:16 ET

EyePoint Pharmaceuticals To Highlight DURAVYUTM Clinical And Regulatory Developments At R&D Day 2024

– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 –– Positive twelv

BenzingaJun 26 08:06 ET

EyePoint Pharmaceuticals (NASDAQ:EYPT Shareholders Incur Further Losses as Stock Declines 12% This Week, Taking Five-year Losses to 51%

Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big losses. For example the EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) share price drop

Simply Wall StJun 21 07:00 ET